Gilead appoints former Roche executive

Gilead Sciences has hired Rogers Luo as vice president and general manager of commercial operations in China. Luo formerly served as vice president at Shanghai Roche Pharmaceuticals.
His primary remit will be building the company’s commercial operations in China, preparing the potential launch of its hepatitis C and B treatments over the next few years.
Several of the firm’s drugs including Sovaldi remain unavailable to patients in the country thanks to a lengthy approval process which can cause years of delays. It will be Luo’s job to spearhead these issues in the region.
The Chinese Food and Drug Administration (CFDA) announced earlier this year that it seeking to revamp its processes, and noted that both Sovaldi and another Gilead product Harvoni would receive priority review, though it is not known how far away this may be.
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- Gilead names Roche veteran Daniel O'Day as new CEO
- Genentech's retiring R&D head to be replaced by MIT executive
- COVID-19: Gilead freezes compassionate access to remdesivir due to "overwhelming demand", BMS and Lilly delay new study launches
- Long-term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
- Gilead's CFO and Executive Vice President to depart in 2020